EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Does lower dose pilocarpine have a role in radiation-induced xerostomia in the modern radiotherapy era? A single-center experience based on patient-reported outcome measures

Dilek Gül, Beste M Atasoy, Ece Ercan, Zilan Başkan, Kıvanç Bektaş Kayhan

European Archives of Oto-Rhino-Laryngology · 2024

DOI: 10.1007/s00405-024-08616-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2024. Verfasst von Dilek Gül und 4 weiteren Autor:innen. Beteiligte Einrichtung: S.B.-Marmara University Pendik Education and Research Hospital Radiation Oncology Clinic, Istanbul, Turkey. Hauptthemen laut MEDLINE: Xerostomia, Pilocarpine, Patient Reported Outcome Measures, Head and Neck Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marmara University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aims to investigate the efficacy of lower dose pilocarpine in alleviating late dry mouth symptoms in head and neck cancer patients received radiotherapy.

Methods

Eighteen head and neck cancer patients experiencing persistent dry mouth were enrolled in this study. All participants started pilocarpine treatment a median of 6 months post-radiotherapy. Initially, patients received pilocarpine at 5 mg/day, with a gradual increase to the recommended dose of 15 mg/day. A Patient-Reported Outcome Measurement (PROMs) questionnaire assessed symptoms’ severity related to hyposalivation.

Results

All patients reported symptomatic dry mouth above grade 2 before starting the medication. Pilocarpine treatment continued based on patients’ self-assessment, with a median duration of 12 months (range, 3–36 months). The median daily maintenance dose was 10 mg (range, 5 to 20 mg). Total PROMs scores significantly decreased following medication, from 13 points (range 7–18 points) to 7 points (range 4–13 points) ( p = 0.001). Significant improvements were observed in questions related to dry mouth ( p < 0.001), water intake during eating ( p = 0.01), carrying water ( p = 0.01), taste ( p < 0.001), and water intake during speech ( p < 0.001). Initial and maintenance doses of pilocarpine were lower, and the duration of pilocarpine usage was shorter in patients treated with intensity-modulated radiation therapy compared to conformal radiotherapy (12 months vs. 25 months, p = 0.04).

Conclusion

Pilocarpine may be considered at doses lower for late-term dry mouth. With modern radiotherapy techniques effectively preserving the parotid gland, short-term use may be recommended in these patients. Future studies may enhance the development of a more robust patient selection criteria model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

XerostomiaPilocarpinePatient Reported Outcome MeasuresHead and Neck NeoplasmsMuscarinic AgonistsRadiation InjuriesHumansMaleFemaleMiddle AgedAgedAdultTreatment Outcome

Stichwörter der Autor:innen

Lower dosePatient-reported outcome measurementPilocarpineRadiotherapyXerostomia

Substanzen

PilocarpineMuscarinic Agonists

Autor:innen und Institutionen

  • S.B.-Marmara University Pendik Education and Research Hospital Radiation Oncology Clinic, Istanbul, Turkey.
  • Department of Radiation Oncology, School of Medicine, Marmara University, Istanbul, Turkey. bmatasoy@marmara.edu.tr.
  • Marmara Üniversitesi Pendik EAH Radyasyon Onkolojisi Kliniği, Fevzi Çakmak Mah. Muhsin Yazıcıoğlu Cad. No: 8, 34899, Istanbul, Turkey. bmatasoy@marmara.edu.tr.
  • Department of Radiation Oncology, School of Medicine, Marmara University, Istanbul, Turkey.
  • Department of Oral and Maxillofacial Surgery, İstanbul University Faculty of Dentistry, Istanbul, Turkey.

Förderung

  • Marmara University

Zitieren

APA

Gül, D., Atasoy, B. M., Ercan, E., Başkan, Z., & Bektaş Kayhan, K. (2024). Does lower dose pilocarpine have a role in radiation-induced xerostomia in the modern radiotherapy era? A single-center experience based on patient-reported outcome measures. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-024-08616-x

Vancouver

Gül D, Atasoy BM, Ercan E, Başkan Z, Bektaş Kayhan K. Does lower dose pilocarpine have a role in radiation-induced xerostomia in the modern radiotherapy era? A single-center experience based on patient-reported outcome measures. European Archives of Oto-Rhino-Laryngology. 2024. doi:10.1007/s00405-024-08616-x

BibTeX
@article{Gl2024,
  author = {Gül, Dilek and Atasoy, Beste M and Ercan, Ece and Başkan, Zilan and Bektaş Kayhan, Kıvanç},
  title = {Does lower dose pilocarpine have a role in radiation-induced xerostomia in the modern radiotherapy era? A single-center experience based on patient-reported outcome measures},
  journal = {European Archives of Oto-Rhino-Laryngology},
  year = {2024},
  doi = {10.1007/s00405-024-08616-x}
}
Kostenlos starten →